Statement Of Changes In Equity [Abstract]

ABIONYX Pharma - Filing #2816648

Concept	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-01-01	As at 2020-01-01	As at 2020-01-01	As at 2020-01-01	As at 2020-01-01	As at 2020-01-01
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	201,000 EUR	169 829 EUR	—	—	10 677 EUR	—	10,000 EUR	179 214 EUR	—	87,000 EUR	1 396 EUR	—	—	—	1 232 EUR	5,000 EUR	136,000 EUR	39,000 EUR	164 822 EUR	170 322 EUR	—	—	6 629 EUR	—	110,000 EUR	163 034 EUR	6 666 EUR	1 097 EUR	168 621 EUR	92,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	—	—	—	5 822 EUR	—	—	—	—	—	—	—	5 822 EUR	1 886 EUR	—	—	—	—	—	—	—	1 886 EUR	—	—	—	—	—	—	—	—	—
Comprehensive income	—	—	—	—	—	—	—	—	—	—	—	5 759 EUR	1 891 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Issue of equity	—	—	—	—	—	8 892 EUR	—	—	164,000 EUR	—	—	9 056 EUR	1 836 EUR	—	—	—	—	—	—	—	—	135,000 EUR	—	1 701 EUR	—	—	—	—	—	—
Increase (decrease) through treasury share transactions, equity	—	—	65,000 EUR	—	—	—	—	—	—	—	—	65,000 EUR	26,000 EUR	26,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	—	—	—	815,000 EUR	—	—	—	—	—	—	—	815,000 EUR	98,000 EUR	—	—	—	—	—	—	—	98,000 EUR	—	—	—	—	—	—	—	—	—